Here's how I think the CSL share price might end 2024

The company continues pushing ahead.

| More on:
Scientists working in the laboratory and examining results.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Ltd (ASX: CSL) share price sold off sharply earlier this week but has since staged a recovery.

At Friday's close, the biotech giant was trading at $308 per share, up more than 4% over the past month.

Analysts believe the biotech giant could end the year on a high note. Here's what I see for the CSL shared based on the expert's opinions.

Created with Highcharts 11.4.3CSL PriceZoom1M3M6MYTD1Y5Y10YALL1 Aug 20239 Aug 2024Zoom ▾Sep '23Nov '23Jan '24Mar '24May '24Jul '24Oct '23Oct '23Jan '24Jan '24Apr '24Apr '24Jul '24Jul '24www.fool.com.au

Why CSL could finish strong in 2024

CSL is one of the best-known stocks on the ASX, so any information or updates on the company are usually digested fairly quickly.

And while things have been quiet from the company's end lately, it's been anything but from the crowd of analysts covering the stock.

Bell Potter recently issued a buy rating with a price target of $327.42 on the CSL share price.

According to my colleague James, the broker reckons that CSL's current share price offers an attractive entry point, especially compared to historical averages.

At the time of its report, CSL was trading at a forward price-to-earnings (P/E) ratio of around 28 times. This is below its 10-year average of 31 times and well under its five-year average of 35 times, Bell Potter says.

The broker notes this disconnection could create a solid buying opportunity, adding that CSL might be on the verge of a "margin recovery phase".

Macquarie also has a buy rating on CSL, with a price target of $330, whilst consensus also sees it as a buy, according to CommSec.

Fundamentals shine amid volatility

CSL stands out as a 'sleep-well-at-night' (SWAN) stock in the healthcare sector, in my opinion.

Healthcare is a defensive industry, and companies like CSL tend to be resilient during economic downturns. For instance, during the COVID-19 recession, CSL continued to deliver steady revenue, showcasing its stability.

Another strength is CSL's long history of generating high returns on capital. In the first half of FY24, CSL reported an 11% increase in revenue to US$8.05 billion. Net profits were up 20% to US$1.94 billion.

CSL's financial position is expected to strengthen further. Bell Potter anticipates that CSL will continue to reduce its debt.

Meanwhile, UBS forecasts earnings per share (EPS) are expected to reach roughly AUD$9.45.

Here I will take a more conservative P/E ratio than where CSL trades today of 35 times. If investors pay this multiple, this could see the CSL share price rise to around $330 per share by year-end.

If they continue paying the current 38 times, the share price could be $359, according to UBS' estimates (38 x 9.45 = $359).

CSL share price snapshot

Based on broker opinions and a range of valuation multiples, my estimation is that the CSL share price could trade between $330 and $359 per share by the end of this year.

CSL shares are up 16% in the past 12 months.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »